Abstract
Measurement of quantitative antibody responses are increasingly important in evaluating the immune response to infection and vaccination. In this study we describe the validation of a quantitative, multiplex serologic assay utilising an electrochemiluminescence platform, which measures IgG against the receptor binding domain (RBD), spike S1 and S2 subunits and nucleocapsid antigens of SARS-CoV-2. The assay displayed a sensitivity ranging from 73-91% and specificity from 90 to 96% in detecting previous infection with SARS-CoV-2 depending on antigenic target and time since infection, and this assay highly correlated with commercially available assays. The within-plate coefficient of variation ranged from 3.8-3.9% and the inter-plate coefficient of variation from 11-13% for each antigen.
Competing Interest Statement
Eoin Feeney has received consulting fees from Gilead, ViiV and Vidacare Ireland. Eoghan de Barra has received consulting fees from Sanofi Pasteur and honoraria/travel grant from Pfizer. Patrick Mallon has received honoraria and/or travel grants from Gilead Sciences, MSD, Bristol Myers Squibb, and ViiV Healthcare.
Funding Statement
This work was supported by Science Foundation Ireland (grant numbers 20/COV/0305 and 20/COV/8549) and a philanthropic donation from Smurfit Kappa and the VACCELERATE the European Corona Vaccine Trial Accelerator Platform. GK is funded through a fellowship from the United States Embassy in Ireland.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Office of the National Research Ethics Committee Ireland St. Vincents Healthcare Group, Ethics and Medical Research Committee and the Mater Misericordiae University Hospital gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Access to pseudonymised data can be requested by submission to the All Ireland Infectious Diseases Cohort steering group, access will be granted depending on a data protection impact assessment and assessment of the research proposal.
